Australia’s Telix Pharma agrees to buy Germany’s ITM Isotope for about $1.65 billion

Sept 21 (Reuters) – Australia’s Telix Pharmaceuticals ​said ‌on Monday it has ‌agreed ​to ⁠acquire Germany-based ⁠ITM Isotope Technologies Munich SE for ​about $1.65 billion ⁠on ⁠a ​cash- and ​debt-free basis.

After adjustments, ‌ITM shareholders are expected ⁠to receive about $1.25 billion ⁠in Telix ‌shares ⁠at $11.84 ​per ‌share.

(Reporting by ​Sneha ⁠Kumar in Bengaluru; Editing by Aurora ​Ellis)